|
1
|
Toss A, De Matteis E, Rossi E, Casa LD,
Iannone A, Federico M and Cortesi L: Ovarian cancer: can proteomics
give new insights for therapy and diagnosis? Int J Mol Sci.
14:8271–8290. 2013.
|
|
2
|
Zhang B, Cai FF and Zhong XY: An overview
of biomarkers for the ovarian cancer diagnosis. Eur J Obstet
Gynecol Reprod Biol. 158:119–123. 2011.
|
|
3
|
Xu YZ, Xi QH, Ge WL and Zhang XQ:
Identification of serum microRNA-21 as a biomarker for early
detection and prognosis in human epithelial ovarian cancer. Asian
Pac J Cancer Prev. 14:1057–1060. 2013.
|
|
4
|
Zhang B, Barekati Z, Kohler C, Radpour R,
Asadollahi R, Holzgreve W and Zhong XY: Proteomics and biomarkers
for ovarian cancer diagnosis. Ann Clin Lab Sci. 40:218–225.
2010.
|
|
5
|
Zhang Z, Bast RC Jr, Yu Y, et al: Three
biomarkers identified from serum proteomic analysis for the
detection of early stage ovarian cancer. Cancer Res. 64:5882–5890.
2004.
|
|
6
|
Jacobs I, Davies AP, Bridges J, et al:
Prevalence screening for ovarian cancer in postmenopausal women by
CA 125 measurement and ultrasonography. BMJ. 306:1030–1034.
1993.
|
|
7
|
Goswamy RK, Campbell S and Whitehead MI:
Screening for ovarian cancer. Clin Obstet Gynaecol. 10:621–643.
1983.
|
|
8
|
Sarojini S, Tamir A, Lim H, et al: Early
detection biomarkers for ovarian cancer. J Oncol.
2012:7090492012.
|
|
9
|
Jacobs IJ, Skates S, Davies AP, et al:
Risk of diagnosis of ovarian cancer after raised serum CA 125
concentration: a prospective cohort study. BMJ. 313:1355–1358.
1996.
|
|
10
|
Anderson GL, McIntosh M, Wu L, et al:
Assessing lead time of selected ovarian cancer biomarkers: a nested
case-control study. J Natl Cancer Inst. 102:26–38. 2010.
|
|
11
|
Bast RC Jr, Boyer CM, Jacobs I, et al:
Cell growth regulation in epithelial ovarian cancer. Cancer. 71(4
Suppl): 1597–1601. 1993.
|
|
12
|
Moradi MM, Carson LF, Weinberg B, Haney
AF, Twiggs LB and Ramakrishnan S: Serum and ascitic fluid levels of
interleukin-1, interleukin-6, and tumor necrosis factor-alpha in
patients with ovarian epithelial cancer. Cancer. 72:2433–2440.
1993.
|
|
13
|
Luo LY, Katsaros D, Scorilas A, et al: The
serum concentration of human kallikrein 10 represents a novel
biomarker for ovarian cancer diagnosis and prognosis. Cancer Res.
63:807–811. 2003.
|
|
14
|
Milojkovic M, Hrgovic Z, Hrgovic I, Jonat
W, Maass N and Buković D: Significance of CA 125 serum level in
discrimination between benign and malignant masses in the pelvis.
Arch Gynecol Obstet. 269:176–180. 2004.
|
|
15
|
Yoo BC, Kong SY, Jang SG, et al:
Identification of hypoxanthine as a urine marker for non-Hodgkin
lymphoma by low-mass-ion profiling. BMC Cancer. 10:552010.
|
|
16
|
McCully KS: Chemical pathology of
homocysteine. III Cellular function and aging. Ann Clin Lab Sci.
24:134–152. 1994.
|
|
17
|
Becker A, Vezmar S, Linnebank M, Pels H,
Bode U, Schlegel U and Jaehde U: Marked elevation in homocysteine
and homocysteine sulfinic acid in the cerebrospinal fluid of
lymphoma patients receiving intensive treatment with methotrexate.
Int J Clin Pharmacol Ther. 45:504–515. 2007.
|
|
18
|
Quinn CT, Griener JC, Bottiglieri T,
Hyland K, Farrow A and Kamen BA: Elevation of homocysteine and
excitatory amino acid neurotransmitters in the CSF of children who
receive methotrexate for the treatment of cancer. J Clin Oncol.
15:2800–2806. 1997.
|
|
19
|
Qiu Y, Zhou B, Su M, et al: Mass
spectrometry-based quantitative metabolomics revealed a distinct
lipid profile in breast cancer patients. Int J Mol Sci.
14:8047–8061. 2013.
|
|
20
|
Ressom HW, Xiao JF, Tuli L, et al:
Utilization of metabolomics to identify serum biomarkers for
hepatocellular carcinoma in patients with liver cirrhosis. Anal
Chim Acta. 743:90–100. 2012.
|
|
21
|
Sakai M, Miyazaki A, Hakamata H, et al:
Lysophosphatidylcholine plays an essential role in the mitogenic
effect of oxidized low density lipoprotein on murine macrophages. J
Biol Chem. 269:31430–31435. 1994.
|
|
22
|
Fang X, Gaudette D, Furui T, et al:
Lysophospholipid growth factors in the initiation, progression,
metastases, and management of ovarian cancer. Ann NY Acad Sci.
905:188–208. 2000.
|
|
23
|
Guo Y, Wang X, Qiu L, et al: Probing
gender-specific lipid metabolites and diagnostic biomarkers for
lung cancer using Fourier transform ion cyclotron resonance mass
spectrometry. Clin Chim Acta. 414:135–141. 2012.
|
